Elotuzumab in Combination with Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone for Relapsed/Refractory MM


Elotuzumab in Combination with Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone for Relapsed/Refractory MM
Slides from presentations at ASH 2015 and transcribed comments from a recent interview with Noopur Raje, MD (2/10/16)
Dimopoulos MA et al. Eloquent-2 update: A phase 3, randomized, open-label study of elotuzumab in combination with lenalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma — 3–year safety and efficacy follow-up. Proc ASH 2015;Abstract 28.

Palumbo A et al. Elotuzumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma: 2-year follow-up. Proc ASH 2015;Abstract 510.

Dr Raje is Director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center and Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts.